Currently, amylin and amylin analogs are considered as potential therapeutic candidates for diabetes as well as for cognitive improvement in patients with AD (Grizzanti, Lee, Camins, Pallas, & Casadesus, 2016; Wang et al., 2017). The gene discussed is IAPP; the disease is Alzheimer disease.